Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01996644
Other study ID # 201212062
Secondary ID F31MH096433-01
Status Completed
Phase N/A
First received November 18, 2013
Last updated March 26, 2018
Start date February 2013
Est. completion date February 2014

Study information

Verified date March 2018
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot study investigating if cycloserine (DCS; a learning enhancement medication) augments exposure therapy for food anxiety in patients with anorexia and bulimia nervosa. The investigators expect that (a) exposure therapy will reduce anxiety (b) anxiety will be reduced more in the DCS relative to placebo condition (c) participants in the DCS condition will have a greater increase in Body Mass Index.


Description:

This study investigated if DCS vs placebo augmented food exposure in individuals with eating disorders.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date February 2014
Est. primary completion date February 2014
Accepts healthy volunteers No
Gender All
Age group 14 Years to 65 Years
Eligibility Inclusion Criteria:

- Diagnosed with Anorexia Nervosa, Bulimia Nervosa, Eating Disorder Not Otherwise Specified

Exclusion Criteria:

- Pregnant or planning on becoming pregnant

- Psychotic or Manic

Study Design


Intervention

Drug:
Placebo vs Setraline
Placebo
Setraline
250mg DCS

Locations

Country Name City State
United States Washington University Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Fear of Food Measure The Fear of Food Measure (FOFM) was designed to assess three cognitive behavioral components related to mealtime anxiety. All items are rated on a 1 to 7 Likert-type scale ranging from "not at all" to "very much so." Higher values indicate worse outcomes. The first subscale is the anxiety about eating subscale, which was designed to assess trait levels of fear and anxiety surrounding eating and food. This subscale will be measured once before and after the trial (twice in 2 weeks). Each item (8 items totaled, each scored 1-7; max possible score is 56; min possible score is 8) was added for each time point and time points were averaged together for all participants for both time points. Twice during 2 weeks
Primary Anxiety as Measured by the Subjective Units of Distress (Ranging From 1 to 100). Anxiety will be measured at 4 sessions, twice a week for two weeks. Anxiety is combined in a repeated measures ANOVA to give total anxiety decreased across condition.
Anxiety was measured using the Subjective Units of Distress (ranging from 1 to 100), where 1 is no anxiety and 100 is the most anxiety ever experienced.
Twice a week for two weeks
Primary Body Mass Index BMI will be measured twice a week for two weeks and once before starting the trial. BMI is combined in a repeated measures ANOVA to give total BMI difference across condition.Difference in BMI from Time 1 to Time 4 was outcome. twice a week for two weeks and at initial assessment